SCHEMBL5741229

SCHEMBL5741229

Cc1ccc(S(=O)(=O)NCCCCCCCCCCCCC(C)C)cc1

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 14/20 0.62
CA12 O43570 1/20 0.59
CA2 P00918 1/20 0.59
CA9 Q16790 1/20 0.59
HTT P42858 1/20 0.58
ALOX15 P16050 1/20 0.57
LMNA P02545 3/20 0.57
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
PKM P14618 3/20 0.54
GBA1 P04062 1/20 0.54
MBTD1 Q05BQ5 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
KDM4E B2RXH2 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
TSHR P16473 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19362573 1.00 ALDH1A1 (0.62) ALDH1A1CA12CA2CA9HTT
SCHEMBL13251389 0.98 ALDH1A1 (0.64) ALDH1A1CA12CA2CA9HTT
SCHEMBL20730799 0.94 ALDH1A1 (0.66) ALDH1A1CA12CA2CA9HTT
SCHEMBL7095193 0.88 ALDH1A1 (0.77) ALDH1A1CA12CA2CA9HTT
SCHEMBL7092896 0.88 ALDH1A1 (0.77) ALDH1A1CA12CA2CA9HTT
SCHEMBL7097551 0.88 ALDH1A1 (0.77) ALDH1A1CA12CA2CA9HTT
SCHEMBL7093365 0.88 ALDH1A1 (0.77) ALDH1A1CA12CA2CA9HTT
SCHEMBL7095949 0.88 ALDH1A1 (0.77) ALDH1A1CA12CA2CA9HTT
SCHEMBL7095731 0.88 ALDH1A1 (0.77) ALDH1A1CA12CA2CA9HTT
SCHEMBL20327817 0.87 ALDH1A1 (0.62) ALDH1A1CA12CA2CA9HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7129366-B2 Group of a novel anti-cancer compounds with specific structure YANG'S BIOCHEM CO. LTD. (US) 2006-10-31 US claimed
EP-1463707-A4 A GROUP OF NOVEL ANTI-CANCER COMPOUNDS WITH SPECIFIC STRUCTURE YANG ZHENHUA (US) 2006-02-01 EP claimed
US-20040204599-A1 Group of novel anti-cancer compounds with specific structure YANG'S BIOCHEM CO. LTD. 2004-10-14 US claimed
EP-1463707-A2 A GROUP OF NOVEL ANTI-CANCER COMPOUNDS WITH SPECIFIC STRUCTURE Yang, Zhenhua (US) 2004-10-06 EP claimed
WO-2003014296-A2 A GROUP OF NOVEL ANTI-CANCER COMPOUNDS WITH SPECIFIC STRUCTURE YANG ZHENHUA (US) 2003-02-20 WO claimed
US-7129366-B2 Group of a novel anti-cancer compounds with specific structure YANG'S BIOCHEM CO. LTD. (US) 2006-10-31 US disclosed
US-20040204599-A1 Group of novel anti-cancer compounds with specific structure YANG'S BIOCHEM CO. LTD. 2004-10-14 US disclosed
CN-1343650-A Anticancer compound with particular structure YANG ZHENHUA (CN) 2002-04-10 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204599-A1 Group of novel anti-cancer compounds with specific structure FASN, NFKBIA, NFATC1 ALDH1A1 3568/4885CA12 3960/4885CA2 4605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.